Effect of Pabolizumab Combined with Intensity Modulated Radiotherapy on Immune Function and Prognosis of HER2 Positive Breast Cancer Patients
ZHENG Xiaona
WANG Lei
HU Yingliang
XU Hui
LI Hui
Abstract：Objective To investigate the effect of pabolizumab combined with intensity modulated radiotherapy(IMRT)on immune function and prognosis of patients with human epidermal growth factor receptor 2(HER2)positive breast cancer.Methods This study utilised retrospective research methods to analyse the clinical data of 128 HER2-positive breast cancer patients from Zhengzhou Central Hospital Affiliated to Zhengzhou University,over the period from January 2021 to June 2023.The patients were segmented into two groups:a study group and a control group,with the allocation to these groups determined by postoperative treatment protocols.The study group received pabolizumab combined with IMRT radiotherapy,while the control group received pabolizumab monotherapy.The clinical efficacy[objective remission rate(ORR),disease control rate(DCR)]and immune function(CD3+、CD4+、C D8+、CD4+/CD8+)were compared between the two groups.The patients were followed-up for one year and compare overall survival after one year of treatment in both groups.Results There was no significant difference in ORR between the two groups(P＞0.05).DCR of study group was[79.69％(51/64)]higher than that of control group[(62.50％(40/64)](P＜0.05).There was no significant difference in CD3+,CD4+and CD4+/CD8+between the two groups before treatment(P＞0.05).After 4 cycles of treatment,CD3+and CD4+in the study group were higher than those in the control group(P＜0.05),and CD4+/CD8+were lower than those in the control group(P＜0.05).Compared with before treatment,both CD3+and CD4+increased and CD4+/CD8+decreased(P＜0.05).After a one year follow-up,the overall survival rate was 100.00％(64/64)in the study group and 96.88％(62/64)in the control group,and the difference was not statistically significant(P＞0.05).Conclusion Pabolizumab combined with IMRT is effective in the treatment of HER2 positive breast cancer patients,which can improve their immune function and prolong their survival time.
Keywords：breast cancerhuman epidermal growth factor receptor 2pabolizumabintensity modulated radiotherapyimmune functionprognosis
Publication Date：2025-03-28
Online Publishing Date：2026-09-12(First online date of this platform, not the publication date of the document)
Pages：4( 1017-1020 )